Celecoxib shows benefits for adenoma prevention, but CV risks remain

05/14/2011 | Reuters

Patients who regularly took the COX-2 selective NSAID celecoxib (Pfizer's Celebrex) over three years were less likely to develop colorectal polyps, but after two years off treatment, the celecoxib group was more likely than the placebo group to have new adenomas, according to a study in The American Journal of Gastroenterology. The report by researchers at Israel's Tel Aviv University -- supported by Pfizer -- looked at data from 1,561 patients with a history of colon adenomas. More than half took celecoxib for about three years before concerns over cardiovascular risks ended the project. Read the abstract.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Actuarial Services, Government Programs
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC